Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015).

Autor: Bliss JM; Clinical Trials and Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK. Judith.bliss@icr.ac.uk., Tovey H; Clinical Trials and Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK., Evans A; Poole Hospital, Poole, UK., Holcombe C; Royal Liverpool University Hospital, Liverpool, UK., Horgan K; Department of Breast Surgery, St James's University Hospital, Leeds, UK., Mallon E; Western Infirmary, Glasgow, UK., Vidya R; Royal Wolverhampton NHS Trust, Wolverhampton, UK., Skene A; Royal Bournemouth Hospital, Bournemouth, UK., Dodson A; UK NEQAS for Immunocytochemistry and In-Situ Hybridisation, London, UK., Hills M; Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital, and Breast Cancer Now Centre, The Institute of Cancer Research, London, UK., Detre S; Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital, and Breast Cancer Now Centre, The Institute of Cancer Research, London, UK., Zabaglo L; Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital, and Breast Cancer Now Centre, The Institute of Cancer Research, London, UK., Banerji J; Clinical Trials and Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK., Kilburn L; Clinical Trials and Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK., Morden JP; Clinical Trials and Statistics Unit (ICR-CTSU), The Institute of Cancer Research, London, UK., Robertson JFR; Royal Derby Hospital, University of Nottingham, Derby, UK., Smith I; Breast Unit, Royal Marsden Hospital, London, UK., Dowsett M; Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital, and Breast Cancer Now Centre, The Institute of Cancer Research, London, UK.

Publikováno v: Breast cancer research : BCR [Breast Cancer Res] 2023 Apr 12; Vol. 25 (1), pp. 39. Date of Electronic Publication: 2023 Apr 12.

Secretion Of Immunoreactive Calcitonin By Human Breast Carcinomas

Autor: Coombes, R. C., Easty, G. C., Detre, S. I., Hillyard, C. J., Stevens, U., Girgis, S. I., Galante, L. S., Heywood, L., Macintyre, I., Neville, A. M.

Publikováno v: The British Medical Journal, 1975 Oct . 4(5990), 197-199.

Externí odkaz: https://www.jstor.org/stable/20407285

Supraphysiological Dose of Testosterone Impairs the Expression and Distribution of Sex Steroid Receptors during Endometrial Receptivity Development in Female Sprague–Dawley Rats.

Autor: Yusuf, Allia Najmie Muhammad^1,2 (AUTHOR) allia.najmie@ums.edu.my, Amri, Mohd Fariz³ (AUTHOR) fariz@ums.edu.my, Ugusman, Azizah¹ (AUTHOR) dr.azizah@ppukm.ukm.edu.my, Hamid, Adila A¹ (AUTHOR) adilahamid@ppukm.ukm.edu.my, Mokhtar, Mohd Helmy¹ (AUTHOR) helmy@ukm.edu.my

Publikováno v: International Journal of Molecular Sciences. Sep2024, Vol. 25 Issue 18, p10202. 17p.

The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer.

Autor: Cocce KJ; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA., Jasper JS; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA., Desautels TK; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA., Everett L; Department of Biological Sciences, North Carolina State University, Raleigh, NC 27695, USA., Wardell S; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA., Westerling T; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA., Baldi R; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA., Wright TM; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA., Tavares K; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA., Yllanes A; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA., Bae Y; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA., Blitzer JT; Viba Therapeutics, San Francisco, CA 94158, USA., Logsdon C; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA., Rakiec DP; Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, MA 02139, USA., Ruddy DA; Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, MA 02139, USA., Jiang T; Department of Biostatistics, Duke Cancer Institute, Duke University School of Medicine, Durham, NC 27710, USA., Broadwater G; Department of Biostatistics, Duke Cancer Institute, Duke University School of Medicine, Durham, NC 27710, USA., Hyslop T; Department of Biostatistics, Duke Cancer Institute, Duke University School of Medicine, Durham, NC 27710, USA., Hall A; Department of Pathology, Duke University School of Medicine, Durham, NC 27710, USA., Laine M; The Ben May Department for Cancer Research, The University of Chicago, Chicago, IL 60637, USA., Phung L; The Ben May Department for Cancer Research, The University of Chicago, Chicago, IL 60637, USA., Greene GL; The Ben May Department for Cancer Research, The University of Chicago, Chicago, IL 60637, USA., Martin LA; Breast Cancer Now, Toby Robins Research Centre, Institute of Cancer Research, London, SW3 6JB, UK., Pancholi S; Breast Cancer Now, Toby Robins Research Centre, Institute of Cancer Research, London, SW3 6JB, UK., Dowsett M; Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital NHS Trust, London, SW3 6JJ, UK., Detre S; Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital NHS Trust, London, SW3 6JJ, UK., Marks JR; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA., Crawford GE; Department of Pediatrics, Duke University School of Medicine, Durham, NC 27710, USA., Brown M; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA., Norris JD; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA., Chang CY; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA., McDonnell DP; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA. Electronic address: donald.mcdonnell@duke.edu.

Publikováno v: Cell reports [Cell Rep] 2019 Oct 22; Vol. 29 (4), pp. 889-903.e10.

Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer

Autor: Lr, Kelland, Smith V, Valenti M, Patterson L, Paul Clarke, Detre S, End D, Aj, Howes, Dowsett M, Workman P, Sr, Johnston

Publikováno v: Europe PubMed Central

Antitumor and pharmacodynamic studies were performed in MCF-7 human breast cancer cells and companion xenografts with the farnesyl protein transferase inhibitor, R115777, presently undergoing Phase II clinical trials, including in breast cancer. R115

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::4d3aa8da34c802e0ea4bed7f3109d23f
https://pubmed.ncbi.nlm.nih.gov/11705875